Nirsevimab, Maternal RSV Vaccine Linked To Decreased Risk For ICU Admission Among Pediatric Patients, Study Suggests

Infectious Disease Advisor (12/9, McSwiggin) reports, “Nirsevimab and the maternal respiratory syncytial virus (RSV) vaccine may be associated with a decreased risk for intensive care unit (ICU) admission among pediatric patients, according to study results.” Researchers found that “encounters with RSV infections who were not vs were eligible for RSV preventions were associated with greater use of positive pressure ventilation...and vasoactive medication...as well as a higher likelihood of mortality.” The findings were published in JAMA Network Open.